However, the expression level of taurine transporter was negatively correlated with AML-M2 malignancy (Zhou et al. 2020).These results suggest that the plasma abundance of taurine has the potential to serve as a prognostic marker for patients with AML-M2. Here, SLC6A6 is linked to acute myeloid leukemia.